Opendata, web and dolomites

BrEXo-Apt TERMINATED

Non-invasive and accurate diagnosis and treatment of breast cancer.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BrEXo-Apt project word cloud

Explore the words cloud of the BrEXo-Apt project. It provides you a very rough idea of what is the project "BrEXo-Apt" about.

strategy    samples    released    compounds    glioma    treatment    indicate    progresses    tissues    exosomes    micrornas    activator    exosome    quintavalle    screening    dr    attracted    antisense    instrumental    interfering    innovative    diagnostic    assay    discriminate    precise    mda231    remove    tests    diagnosis    of    surrounding    surveillance    preliminary    affinity    increasing    patients    platforms    block    metastasis    plasmapheresis    predictive    indicates    types    lung    extracellular    invasive    dnas    overcome    prognostic    cells    therapeutic    aptamer    rnas    breast    categories    drug    angiogenesis    play    aptamers    interfere    interesting    data    earliest    nucleic    internalization    healthy    tumour    acids    bc    generate    progression    invasion    escape    sandwich    larger    circulating    organs    blood    release    recognize    spreading    cancer    detection    patient    inhibition    resistance    biomarkers    evidences    therapy    mainly    immune   

Project "BrEXo-Apt" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Increasing evidences indicate that the release of a great numbers of exosomes by tumour cells play a key role in tumour progression, drug resistance, immune surveillance escape, angiogenesis, tumour invasion and metastasis. For this reason, cancer-derived exosomes are emerging as very interesting targets for cancer therapy and diagnosis. In particular, extracellular exosomes may have great potential as early diagnostic and prognostic biomarkers for many types of cancer, including breast cancer. Early screening methods for breast cancer are mainly based on instrumental tests, that may cause in many cases a failure to reach particular categories of patients. This failure could be overcome with the availability of specific and predictive circulating biomarkers allowing non-invasive earliest tumour detection on a larger scale of patients. Indeed, progresses in developing nucleic acids-based therapeutic compounds, including antisense DNAs, aptamers, short interfering/microRNAs, and short activator RNAs, have attracted great interest as emerging platforms for precise cancer treatment. Dr Quintavalle has identified aptamers that specifically recognize BC-released exosomes and are able to discriminate between breast cancer derived exosome and glioma or lung cancer derived exosomes. Preliminary data indicates also that these aptamers are able to block the internalization of MDA231 derived exosome on MDA231 cells. To develop a new diagnostic and therapeutic strategy, Dr Quintavalle will aim to exploit the identified aptamers to design an innovative aptamer-based sandwich assay for their specific detection in patient blood samples. Moreover, since the inhibition of cancer exosome uptake by surrounding healthy tissues and organs would represent an effective strategy to interfere with tumour spreading and development, Dr. Quintavalle will aim to generate an affinity plasmapheresis system by using BC specific aptamers for specifically remove BC-derived exosome from patient blood.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREXO-APT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREXO-APT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

INFANTPATTERNS (2019)

Development of kinematic and muscle patterns in preterm infants

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More